semaglutide heart failure trial in with preserved ejection fraction: The STEP-HFpEF tested the hypothesis that treatment with semaglutide can significantly improve symptoms, physical limitations and exercise function, in addition to weight loss STEP-HFpEF DM Trial Hints at

We hoped to identify whether specific adjustments to our payment policies for SaaS technologies are needed to more accurately and appropriately pay for these products and services across settings of care

Nat Rev Drug Discov 8:500515 Kooij KL, Koster DIj, Eeltink E et al (2024) GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling

Research demonstrates combined use produces approximately 30% faster healing versus either peptide individually, with enhanced fibroblast activity and immune cell migration

I believe that the notion of oral GLP-1s being a net negative for Stevanato is pretty misguided, for several reasons

B.NesterenkoM